Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Harrow, Inc.
Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.
November 21, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Announces Participation in Upcoming Investor Conferences
November 15, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Announces Third Quarter 2024 Financial Results
November 13, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Launches Access and Affordability Program with Price Reductions for Branded Products
November 13, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Announces Market Access Wins for VEVYE®
November 12, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products
November 07, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024
October 31, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
October 10, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Relaunches TRIESENCE®
October 03, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Announces Nashville Expansion
September 25, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow to Present at Three Investor Conferences in September in New York
September 03, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Announces Second Quarter 2024 Financial Results
August 07, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024
July 25, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow to Attend 2024 ASRS Annual Meeting
July 12, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products
July 09, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Provides TRIESENCE® Relaunch Update
June 20, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
June 05, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow to Present at Two Investor Conferences in May
May 15, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Announces First Quarter 2024 Financial Results
May 13, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
May 13, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
April 25, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
March 19, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
March 05, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
February 15, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Announces New Appointments to its Board of Directors
January 29, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease
January 11, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Partners with Leading Healthcare Market Access Technology Platforms
January 03, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Completes Transfer of the TRIESENCE® New Drug Application
November 29, 2023
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow to Present at Two Investor Conferences in November
November 20, 2023
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Announces Third Quarter 2023 Financial Results
November 13, 2023
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.